GPCR
Structure Therapeutics, Inc.
September 9, 2026 · intraday
- Rarity
- 1.82
- Peak move
- +10.76%
- Float cap
- $2.8B
Structure Therapeutics is a clinical-stage biopharmaceutical company leveraging structure-based drug discovery and computational chemistry to develop oral small-molecule therapies targeting G-protein coupled receptors. Its lead candidate, aleniglipron, is a GLP-1 receptor agonist in clinical trials for obesity and related metabolic conditions, with additional early-stage candidates for diabetes, heart failure, and other chronic diseases.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
3 events · 1 from SEC or newswire · 0 timed with the moveanalyst_ratingCitizens JMP reiterated its Market Outperform rating and $110 price target on Structure Therapeutics after the company reported clinical trial data for its obesity programs.
clinical_readoutStructure Therapeutics reported positive topline results for ACCG-2671, an oral small molecule dual amylin and calcitonin receptor agonist, from the single ascending dose portion of a Phase 1/2a trial, and 72-week results from the ACCESS open-label extension study of aleniglipron, an oral GLP-1 receptor agonist, showing sustained weight loss.
SEC8-K 0001104659-26-105688analyst_ratingJefferies reiterated its Buy rating on Structure Therapeutics and raised its price target to $125 following the company's amylin and GLP-1 clinical data.